PT103029B - Inibidores de dopamina-beta-hidroxilase selectivos perifericamente e metodo paraa sua preparacao - Google Patents

Inibidores de dopamina-beta-hidroxilase selectivos perifericamente e metodo paraa sua preparacao

Info

Publication number
PT103029B
PT103029B PT103029A PT10302903A PT103029B PT 103029 B PT103029 B PT 103029B PT 103029 A PT103029 A PT 103029A PT 10302903 A PT10302903 A PT 10302903A PT 103029 B PT103029 B PT 103029B
Authority
PT
Portugal
Prior art keywords
periphered
dopamine
beta
preparation
hydroxylase inhibitors
Prior art date
Application number
PT103029A
Other languages
English (en)
Other versions
PT103029A (pt
Inventor
Patricio Manuel Vieira A Silva
David Alexander Learmonth
Alexander Beliaev
Original Assignee
Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0223719A external-priority patent/GB2393958A/en
Application filed by Portela & Ca Sa filed Critical Portela & Ca Sa
Publication of PT103029A publication Critical patent/PT103029A/pt
Publication of PT103029B publication Critical patent/PT103029B/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/695Silicon compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
PT103029A 2002-10-11 2003-10-10 Inibidores de dopamina-beta-hidroxilase selectivos perifericamente e metodo paraa sua preparacao PT103029B (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0223719A GB2393958A (en) 2002-10-11 2002-10-11 Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase
GB0224306A GB2394223B (en) 2002-10-11 2002-10-18 Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation

Publications (2)

Publication Number Publication Date
PT103029A PT103029A (pt) 2004-05-31
PT103029B true PT103029B (pt) 2005-05-31

Family

ID=32031889

Family Applications (1)

Application Number Title Priority Date Filing Date
PT103029A PT103029B (pt) 2002-10-11 2003-10-10 Inibidores de dopamina-beta-hidroxilase selectivos perifericamente e metodo paraa sua preparacao

Country Status (13)

Country Link
US (2) US7125904B2 (pt)
EP (5) EP1908760B1 (pt)
JP (1) JP4620464B2 (pt)
KR (1) KR101155159B1 (pt)
AU (1) AU2003271945B2 (pt)
BR (1) BRPI0315143B8 (pt)
CA (1) CA2501819C (pt)
GB (2) GB2432158B (pt)
MX (1) MXPA05003847A (pt)
PL (1) PL218537B1 (pt)
PT (1) PT103029B (pt)
RU (1) RU2332416C2 (pt)
WO (1) WO2004033447A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600709D0 (en) * 2006-01-13 2006-02-22 Portela & Ca Sa Drug combinations
GB0610804D0 (en) * 2006-05-31 2006-07-12 Portela & Ca Sa New crystal forms
RU2009126571A (ru) 2006-12-12 2011-01-20 Биал-Портела Энд Ка, С.А. (Pt) Каталитический способ асимметричной гидрогенизации
GB0700635D0 (en) * 2007-01-12 2007-02-21 Portela & Ca Sa Therapy
GB0701965D0 (en) * 2007-02-01 2007-03-14 Portela & Ca Sa Process
US20100093817A1 (en) * 2007-02-01 2010-04-15 Bial - Portela & Ca S.A. Compounds
GB0701966D0 (en) * 2007-02-01 2007-03-14 Portela & Ca Sa Process
WO2008115706A1 (en) * 2007-03-16 2008-09-25 Emory University Methods and compositions for treatment of drug addiction
GB0708818D0 (en) * 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
GB0709695D0 (en) * 2007-05-21 2007-06-27 Portela & Ca Sa Process
TW200927740A (en) * 2007-11-13 2009-07-01 Bial Portela & Ca Sa Process
WO2009072915A1 (en) 2007-12-05 2009-06-11 Bial - Portela & Ca., S.A. New salts and crystal forms
AR070841A1 (es) * 2008-03-13 2010-05-05 Bial Portela & Ca Sa Proceso de hidrogenacion catalitica asimetrica
KR20110015412A (ko) 2008-03-19 2011-02-15 바이알 - 포르텔라 앤드 씨에이 에스에이 촉매적 비대칭 수소화
US8313984B2 (en) * 2008-03-19 2012-11-20 Ati Technologies Ulc Die substrate with reinforcement structure
AR071632A1 (es) 2008-05-06 2010-06-30 Bial Portela & Ca Sa Proceso catalitico para hidrogenacion asimetrica en la sintesis de inhibidores de la dopamina-beta-hidroxilasa"
EP3238738B1 (en) * 2008-11-10 2020-09-23 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
JP5574480B2 (ja) * 2009-03-12 2014-08-20 国立大学法人高知大学 アミノ基含有アセトン誘導体、及びそれを用いた炭素−炭素結合形成方法
CN104698749B (zh) * 2010-01-25 2019-11-19 罗门哈斯电子材料有限公司 包含含氮化合物的光致抗蚀剂
BR112013015864B1 (pt) * 2010-12-22 2021-11-09 Bial - Portela & C.A., S.A. Processo para purificar um composto de forma cristalina a de (r)-5-(2-benzilamino)etil)-1- (6,8-difluorocroman-3-il)-1h-imidazol-2(3h)-tiona
EP2726454B1 (en) 2011-06-29 2018-01-24 Bial-Portela & CA, S.A. Process
PT2822936T (pt) 2012-03-07 2021-12-02 Univ Of Delhi Derivados da aminoquinolina e suas utilizações
TR201815850T4 (tr) * 2012-11-14 2018-11-21 Bial Portela & Ca Sa Pulmoner arteryel hipertansiyonun ve akciğer hasarının tedavisinde kullanım için 1,3-dihidroimidazol-2-tion türevleri.
GB201316410D0 (en) 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein
JOP20190050A1 (ar) * 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
US11434242B2 (en) 2017-12-04 2022-09-06 Bial—Portela & Ca, S.A. Dopamine-b-hydroxylase inhibitors
GB201810395D0 (en) 2018-06-25 2018-08-08 Bial Portela & Ca Sa Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation
WO2020123699A1 (en) * 2018-12-11 2020-06-18 The Trustees Of Columbia University In The City Of New York Compounds and compositions that cause mycn and/or cmyc degradation and methods of use thereof
GB201908044D0 (en) 2019-06-05 2019-07-17 Bial Portela & Ca Sa Dopamine-B-Hydroxylase inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH22522A (en) 1985-09-03 1988-10-17 Ciba Geigy Ag 3-amino-dihydro-1-benzopyrans and benzothiopyrans, their pharmaceutical compositions and method of using said compounds
EP0295401A3 (de) * 1987-04-30 1990-03-21 Wacker-Chemie Gmbh Verfahren zur Polymerisation von polaren Verbindungen
FR2619113B2 (fr) 1987-05-26 1991-06-28 Exsymol Sa Nouveaux produits de condensation de silanols, leurs preparation et application
US4868210A (en) * 1988-03-30 1989-09-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
US5013854A (en) 1989-02-02 1991-05-07 Eli Lilly And Company Process for preparing acid halides
SE8904361D0 (sv) 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
ES2130135T3 (es) * 1990-01-11 1999-07-01 Upjohn Co Nuevos compuestos heterociclicos de 6,7,8,9-tetrahidro-3h-benz(e)indol con actividad terapeutica sobre el sistema nervioso central.
IT1241988B (it) 1990-06-15 1994-02-02 Sigma Tau Ind Farmaceuti 2- amminotetraline-6, 7-sostituite attive come immunomodulanti e composizioni farmaceutiche che le contengono
DD297249A5 (de) 1990-08-07 1992-01-02 Veb Mineralwollewerk Flechtingen Bereich F/E Mineralwolle,De Verfahren zur automatischen ueberwachung des aushaertegrades an materialbahnen
US5438150A (en) * 1994-04-26 1995-08-01 Syntex (U.S.A.) Inc. Process for making 1-benzocycloalkyl-1,3-dihydroimidazole-2-thione derivatives
US5538988A (en) * 1994-04-26 1996-07-23 Martinez; Gregory R. Benzocycloalkylazolethione derivatives
DE69531102T2 (de) * 1994-04-26 2004-04-29 Roche Palo Alto Llc, Palo Alto Benzocyclohexylimidazolthion-derivate
GB2290790A (en) 1994-06-30 1996-01-10 Merck & Co Inc Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
IT1271009B (it) 1994-09-13 1997-05-26 Zambon Spa Derivati del benzopirano e del benzotiopirano attivi sul sistema cardiovascolare
JPH08259572A (ja) * 1995-01-24 1996-10-08 Toyama Chem Co Ltd 新規なセファロスポリン誘導体またはその塩
IT1278045B1 (it) 1995-03-09 1997-11-17 Sigma Tau Ind Farmaceuti Uso di 2-amminotetraline-6,7-sostituite per la preparazione di composizioni farmaceutiche atte al trattamento dello shock, e di
IT1294931B1 (it) 1997-09-22 1999-04-23 Sigma Tau Ind Farmaceuti Derivati della 2-amminotetralina procedimento per la loro preparazione e composizioni farmaceutiche che li contengono, attive nella
SE9801726D0 (sv) 1998-05-15 1998-05-15 Astra Ab New process
CA2338328A1 (en) 1998-07-21 2000-02-03 Thomas Jefferson University Small molecule inhibitors of bcl-2 proteins
ES2224483T3 (es) 1999-04-19 2005-03-01 General Electric Company Aminas terciarias bis-sililicas.
US20010039343A1 (en) 2000-01-28 2001-11-08 Mulvihill Mark Joseph Process to intermediates for biologically active compounds
DZ3415A1 (fr) * 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
WO2002055112A2 (en) 2001-01-09 2002-07-18 Bristol Myers Squibb Co Polypodal chelants for metallopharmaceuticals

Also Published As

Publication number Publication date
EP1914233B1 (en) 2011-03-02
PL376224A1 (en) 2005-12-27
EP1911757A3 (en) 2008-05-28
GB2432159A (en) 2007-05-16
EP1408038A3 (en) 2004-04-21
EP1408038B1 (en) 2008-08-06
KR20050057647A (ko) 2005-06-16
AU2003271945B2 (en) 2009-12-17
PT103029A (pt) 2004-05-31
GB2432159B (en) 2007-06-27
PL218537B1 (pl) 2014-12-31
CA2501819A1 (en) 2004-04-22
BRPI0315143B8 (pt) 2021-05-25
EP1908760A1 (en) 2008-04-09
BRPI0315143B1 (pt) 2017-02-14
EP1914233B8 (en) 2011-04-13
EP1908759A3 (en) 2008-04-16
EP1911757B1 (en) 2011-03-02
RU2005114021A (ru) 2005-11-10
GB2432158B (en) 2007-06-27
GB0702981D0 (en) 2007-03-28
BR0315143A (pt) 2005-08-16
EP1908759A2 (en) 2008-04-09
WO2004033447A1 (en) 2004-04-22
EP1908759B1 (en) 2012-03-21
GB0702982D0 (en) 2007-03-28
US7125904B2 (en) 2006-10-24
RU2332416C2 (ru) 2008-08-27
EP1914233A1 (en) 2008-04-23
EP1908760B1 (en) 2011-04-13
KR101155159B1 (ko) 2012-06-11
US20070015730A1 (en) 2007-01-18
JP2006507261A (ja) 2006-03-02
US7259271B2 (en) 2007-08-21
JP4620464B2 (ja) 2011-01-26
US20040142996A1 (en) 2004-07-22
AU2003271945A1 (en) 2004-05-04
GB2432158A (en) 2007-05-16
EP1911757A2 (en) 2008-04-16
EP1911757B8 (en) 2011-05-25
CA2501819C (en) 2012-09-04
MXPA05003847A (es) 2005-06-22
EP1408038A2 (en) 2004-04-14

Similar Documents

Publication Publication Date Title
PT103029B (pt) Inibidores de dopamina-beta-hidroxilase selectivos perifericamente e metodo paraa sua preparacao
ITRM20040638A1 (it) Gel piastrinico semisintetico e metodo per la sua preparazione.
BRPI0313238A2 (pt) método
NO20032220D0 (no) Löfteverktöy II og fremgangsmåte for anvendelse av samme
DE60305762D1 (de) Abbildungsgerät und -verfahren
DK1620551T3 (da) Phospholipase og fremgangsmåde til fremstilling deraf
GB0406061D0 (en) Method and system for clearing trades
DE60319191D1 (de) Brückenvorrichtung und -verfahren
DE60327836D1 (de) PVD-Vorrichtung und Verfahren
SE0303177L (sv) Undersökningsmetod och -anordning
DE602004014025D1 (de) Betätigungsvorrichtung und -verfahren
NO20035401D0 (no) Metode
NO20023358D0 (no) Metode
ITTO20030678A1 (it) Metodo e apparecchiatura di determinazione quantitativa
DE60309691D1 (de) Giessvorrichtung und -verfahren
ITPO20030002A1 (it) Orecchino perfezionato e metodo per la sua applicazione
NO20041050L (no) Fremgmgsmate og sammensetninger
DE60300239D1 (de) Tortelefon und Anwendungsverfahren dafür
ITPD20030271A1 (it) Corsetto ortopedico e metodo per la sua realizzazione
SE0201929D0 (sv) Architecture and method
SE0302662D0 (sv) New composition and method
FI20031599A0 (fi) Testausjärjestelmä ja -menetelmä
SE0202781D0 (sv) New composition and method
SE0202583D0 (sv) New method and composition II
SE0202416D0 (sv) Analysis machine and method

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 20040209

FG3A Patent granted, date of granting

Effective date: 20031010